Alector Inc ALEC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
-
Alector to Participate in Upcoming Healthcare Conferences
-
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Alector to Host Mid-Year Earnings Conference Call
-
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
-
Alector, GSK Get FDA Breakthrough Designation for Latozinemab
Trading Information
- Previous Close Price
- $4.93
- Day Range
- $4.81–5.05
- 52-Week Range
- $3.66–8.90
- Bid/Ask
- $4.80 / $6.05
- Market Cap
- $468.11 Mil
- Volume/Avg
- 331,652 / 551,643
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 245
- Website
- https://www.alector.com
Comparables
Valuation
|
Metric
|
ALEC
|
FULC
|
RNA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.11 | 0.91 | 3.77 |
Price/Sales | 7.81 | 3.08 | 342.53 |
Price/Cash Flow | — | — | — |
Price/Earnings
ALEC
FULC
RNA
Financial Strength
|
Metric
|
ALEC
|
FULC
|
RNA
|
|---|---|---|---|
Quick Ratio | 3.41 | 21.84 | 15.61 |
Current Ratio | 3.52 | 22.07 | 15.78 |
Interest Coverage | — | — | — |
Quick Ratio
ALEC
FULC
RNA
Profitability
|
Metric
|
ALEC
|
FULC
|
RNA
|
|---|---|---|---|
Return on Assets (Normalized) | −19.88% | −1.76% | −25.50% |
Return on Equity (Normalized) | −77.59% | −1.91% | −28.88% |
Return on Invested Capital (Normalized) | −62.79% | −1.83% | −33.01% |
Return on Assets
ALEC
FULC
RNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kkgmvrgyps | Kztdv | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ntpcqxqh | Bncmtb | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hvmcslv | Dxrbs | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pqvzdghqy | Mkzwrq | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Dmwvbklr | Snsl | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Jdmymsp | Jqdf | $28.0 Bil | |||
| Moderna Inc
MRNA
| Msppmjkny | Lbpr | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Mznsxfyjp | Stky | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gxxjzmkqk | Tdxbnv | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Bwxpfvqqr | Fwpfw | $12.6 Bil |
United States